Geographic Atrophy (GA) Market to reach USD 50.0 Billion by 2032 and grow at a CAGR of 8.6%.
The Geographic Atrophy (GA) market is experiencing robust growth, fueled by several dynamic factors. Geographic atrophy, a severe form of age-related macular degeneration (AMD), poses a significant global health challenge. According to the American Academy of Ophthalmology, over 8 million people worldwide suffer from GA, which constitutes approximately 20% of all AMD cases. The prevalence of GA is anticipated to rise due to the expanding geriatric population, which is more vulnerable to age-related diseases. The increasing age burden in developed nations amplifies the need for effective GA treatments, driving market growth.